Education
About Us
Working with TipRanks
Follow Us
Prophase Labs (PRPH)
NASDAQ:PRPH
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.51Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -43.18%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The call presented a mix of optimism about future liquidity events and strategic restructuring achievements, balanced by concerns over current financial tightness and low stock price. The company is focusing on turning around its financial position through potential collections and asset sales.Company Guidance
During the call, ProPhase Labs, Inc. CEO Ted Karkus provided guidance on several key metrics and future plans. He highlighted the company's current position and potential liquidity events, including a significant $73 million expected collection from COVID testing accounts receivable, with $50 million anticipated net proceeds. Karkus discussed plans to commercialize the B Smart esophageal cancer test without incurring high costs, emphasizing strategic partnerships as a preferred approach. He mentioned potential sales of subsidiaries like Nebula Genomics, which was acquired for approximately $14 million, as a means to bolster cash flow. The company has undergone significant restructuring, including selling Formulate for $23 million, shutting down high-overhead operations, and reducing headcount to improve profitability. Despite a challenging market environment, Karkus expressed optimism about raising the stock price above the $1 Nasdaq threshold, leveraging potential liquidity events, and focusing on building revenues and working towards profitability.Potential $50 Million Collection from COVID Testing
Crown Medical Collections believes they can collect $50 million from outstanding COVID testing accounts receivable, significantly boosting liquidity.
Sale of Formalize Manufacturing
Formalize Manufacturing was sold for $23 million, which was used to retire most of the company's debt, improving the balance sheet.
Nebula Genomics Restructuring
Nebula Genomics has been restructured with a focus on D to C business, potentially becoming a profit generator in the near future.
Cutting Overhead and Streamlining Operations
Significant reductions in overhead and headcount have been implemented, positioning the company for improved profitability in future quarters.
Exciting Prospects for B Smart Esophageal Cancer Test
The B Smart esophageal cancer test is poised for commercialization, with potential partnerships with large diagnostic companies being explored.
---
PRPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PRPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $0.44 | $0.40 | -9.09% |
| Nov 13, 2024 | $0.74 | $0.77 | +4.05% |
| Aug 14, 2024 | $2.47 | $2.50 | +1.21% |
| May 09, 2024 | $5.39 | $4.92 | -8.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Prophase Labs (PRPH) report earnings?
Prophase Labs (PRPH) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Prophase Labs (PRPH) earnings time?
Prophase Labs (PRPH) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRPH EPS forecast?
PRPH EPS forecast for the fiscal quarter 2025 (Q1) is -0.24.
---